Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 8, 2004. The report details a share repurchase transaction executed on September 7, 2004, and updates regarding directors' interests in company shares.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only specific financial data disclosed relates to the share buyback:
- Shares Purchased: 875,000 Ordinary shares of 25 pence each.
- Purchase Price: 1,136.5674 pence per share.
- Treasury Holdings: 42,193,000 shares held in Treasury following the transaction.
- Shares in Issue: 5,892,188,160 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of outstanding shares through the repurchase of 875,000 shares. Additionally, the GlaxoSmithKline Employee Trust transferred 580 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities.
Investor Verification Points
- Verify the total cost of the share repurchase based on the disclosed price of 1,136.5674 pence per share.
- Confirm the updated total share count and Treasury holdings against subsequent filings.
- Review the impact of the 580-share transfer from the GSK Trust on director interest disclosures.
- Note that this filing does not contain operational or financial performance data for the period.